Comparing PharmaCyte Biotech (OTCMKTS:PMCBD) & Alpha Cognition (OTC:ACOGF)

Alpha Cognition (OTC:ACOGF) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Valuation and Earnings

This table compares Alpha Cognition and PharmaCyte Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alpha Cognition and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Analyst Recommendations

This is a summary of recent ratings for Alpha Cognition and PharmaCyte Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
PharmaCyte Biotech	0	0	0	0	0.00

Given Alpha Cognition’s stronger consensus rating and higher probable upside, research analysts plainly believe Alpha Cognition is more favorable than PharmaCyte Biotech.

Risk & Volatility

Alpha Cognition has a beta of 2.8, meaning that its share price is 180% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.

Summary

Alpha Cognition beats PharmaCyte Biotech on 6 of the 9 factors compared between the two stocks.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.